Research map: Harnessing immunity against breast cancer: from checkpoints to cell therapies

Back to the article

Papers in this map

  1. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries · Freddie Bray · 2024 · 26051 citations · Cited by this paper
  2. Sex- and menopause-related differences in immune and gastrointestinal symptom architecture in ME/CFS: evidence from factor analysis and structural equation modeling · Lotte Habermann-Horstmeier · 2026 · 1 citation · Related
  3. Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer · Peter Schmid · 2018 · 4475 citations · Cited by this paper
  4. Mechanisms and functions of the TRIM protein family in digestive system cancers · 2026 · Related
  5. Pembrolizumab for Early Triple-Negative Breast Cancer · Peter Schmid · 2020 · 3305 citations · Cited by this paper
  6. Advances in manufacturing chimeric antigen receptor immune cell therapies · 2024 · Related
  7. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update · Bryan J. Schneider · 2021 · 2223 citations · Cited by this paper
  8. Deep N-glycoproteomic profiling of FFPE tissues enables precise diagnosis of primary liver cancer from metastatic liver cancer · 2026 · Related
  9. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy · Carsten Denkert · 2017 · 2209 citations · Cited by this paper
  10. Canonical Wnt signaling in the regulation of prostate cancer stem cells: a key driver of castration-resistant prostate cancer and a therapeutic opportunity · 2026 · Related
  11. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial · Javier Cortés · 2020 · 1858 citations · Cited by this paper
  12. Decoding the cholangiocarcinoma tumor microenvironment: from single-cell and spatial atlases to translational therapeutic targeting · 2026 · Related
  13. Cancer immunoediting and resistance to T cell-based immunotherapy · Jake S. O’Donnell · 2018 · 1826 citations · Cited by this paper
  14. Tumour-infiltrating lymphocyte therapy landscape: prospects and challenges · 2025 · Related
  15. Human chimeric antigen receptor macrophages for cancer immunotherapy · Michael Klichinsky · 2020 · 1499 citations · Cited by this paper
  16. Scaling up and scaling out: Advances and challenges in manufacturing engineered T cell therapies · 2022 · Related
  17. Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study · Rita Nanda · 2016 · 1497 citations · Cited by this paper
  18. Immune Checkpoint Inhibitors and Novel Immunotherapy Approaches for Breast Cancer · 2022 · Related
  19. ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer · Alessandra Gennari · 2021 · 1443 citations · Cited by this paper
  20. Tertiary lymphoid structures in breast cancer: Mechanistic insights, subtype-specific patterns, and therapeutic implications · 2026 · Related
  21. Prognostic Value of Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancers From Two Phase III Randomized Adjuvant Breast Cancer Trials: ECOG 2197 and ECOG 1199 · Sylvia Adams · 2014 · 1352 citations · Cited by this paper
  22. Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer · Peter Schmid · 2022 · 1231 citations · Cited by this paper
  23. Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy · Emma C. Morris · 2021 · 1120 citations · Cited by this paper
  24. Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial · Elizabeth Ann Mittendorf · 2020 · 1100 citations · Cited by this paper
  25. Mechanisms of resistance to CAR T cell therapy · Nirali N. Shah · 2019 · 989 citations · Cited by this paper
  26. Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers · Sherene Loi · 2019 · 931 citations · Cited by this paper
  27. Breast cancer: pathogenesis and treatments · Xin Xiong · 2025 · 920 citations · Cited by this paper
  28. Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study · Sylvia Adams · 2018 · 810 citations · Cited by this paper
  29. Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer · Leisha A. Emens · 2018 · 802 citations · Cited by this paper
  30. Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer · David W. Miles · 2021 · 756 citations · Cited by this paper
  31. TRUCKs: the fourth generation of CARs · Markus Martin Chmielewski · 2015 · 735 citations · Cited by this paper
  32. Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer · Rita Nanda · 2020 · 724 citations · Cited by this paper
  33. A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study · S. Loibl · 2019 · 713 citations · Cited by this paper
  34. CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances · Karama Makni‐Maalej · 2023 · 623 citations · Cited by this paper
  35. Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer · Peter Schmid · 2024 · 551 citations · Cited by this paper
  36. Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial · Eric P. Winer · 2021 · 510 citations · Cited by this paper
  37. Dual Targeting of ErbB2 and MUC1 in Breast Cancer Using Chimeric Antigen Receptors Engineered to Provide Complementary Signaling · Scott D. Wilkie · 2012 · 491 citations · Cited by this paper
  38. Open-label Clinical Trial of Niraparib Combined With Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast Cancer · Shaveta Vinayak · 2019 · 460 citations · Cited by this paper
  39. Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study · Peter Schmid · 2020 · 447 citations · Cited by this paper

Source: OpenAlex (CC0)